DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
OrderPoint was designed as an advanced DTR solution from its first release in 2016.
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.
The Supervisory Board has unanimously decided to propose Roy Jakobs as the next President and CEO of Royal Philips to its General Meeting of Shareholders.
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
Company appoints five new independent directors to reconstituted board
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
Subscribe To Our Newsletter & Stay Updated
